Design and Optimization of Selectivity-Tunable Toll-like Receptor 7/8 Agonists as Novel Antibody–Drug Conjugate Payloads

Author:

Patel Akash M.1ORCID,Willingham Aarron2,Cheng Alan C.3ORCID,Tomazela Daniela2,Bowman Eddie4,Kofman Esther2,Zhang Fan2,Bao Jianming5,Sanzone Jillian R.5,Choy Jonathan W.4,Flygare John A.1,Han Jin-Hwan4,Pradhan Komal4,Kieffer Madeleine1,Chernyak Natalia1ORCID,Akbari Peyman4,Liu Ping5,Mehmood Rimsha3ORCID,Naravula Saraswathi2,Hollingsworth Scott A.3ORCID,Bhagwat Bhagyashree2,Lang Simon B.1ORCID,Seganish W. Michael1ORCID

Affiliation:

1. Discovery Chemistry, Merck & Co. Inc., South San Francisco, California 94080, United States

2. Discovery Biologics, Merck & Co. Inc., South San Francisco, California 94080, United States

3. Modeling and Informatics, Merck & Co. Inc., South San Francisco, California 94080, United States

4. Discovery Oncology, Merck & Co. Inc., South San Francisco, California 94080, United States

5. External Discovery Chemistry, Merck & Co. Inc., South San Francisco, California 94080, United States

Publisher

American Chemical Society (ACS)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3